The invention relates to sphingoglycolipid analogues and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist
作者:Benjamin J. Compton、Kathryn J. Farrand、Ching-wen Tang、Taryn L. Osmond、Mary Speir、Astrid Authier-Hall、Jing Wang、Peter M. Ferguson、Susanna T. S. Chan、Regan J. Anderson、Taylor R. Cooney、Colin M. Hayman、Geoffrey M. Williams、Margaret A Brimble、Collin R. Brooks、Lin-Kin Yong、Leonid S. Metelitsa、Dirk M. Zajonc、Dale I. Godfrey、Olivier Gasser、Robert Weinkove、Gavin F. Painter、Ian F. Hermans
DOI:10.1039/c8ob02982b
日期:——
Through chemical synthesis we have designed out the toxicity associated with the powerful vaccine adjuvant α-GalCer.
The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.